Show simple item record

dc.contributor.author Schwenkglenks, M
dc.contributor.author Pettengell, R
dc.contributor.author Szucs, TD
dc.contributor.author Culakova, E
dc.contributor.author Lyman, GH
dc.coverage.spatial England
dc.date.accessioned 2011-06-21T17:30:26Z
dc.date.issued 2010-08-19
dc.identifier http://www.ncbi.nlm.nih.gov/pubmed/20723212
dc.identifier 1756-8722-3-27
dc.identifier.citation J Hematol Oncol, 2010, 3 pp. 27 - ?
dc.identifier.uri http://hdl.handle.net/10161/4389
dc.description.abstract BACKGROUND: In newly diagnosed patients with Hodgkin lymphoma (HL) the effect of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD)-related neutropenia on chemotherapy delivery is poorly documented. The aim of this analysis was to assess the impact of chemotherapy-induced neutropenia (CIN) on ABVD chemotherapy delivery in HL patients. STUDY DESIGN: Data from two similarly designed, prospective, observational studies conducted in the US and the EU were analysed. One hundred and fifteen HL patients who started a new course of ABVD during 2002-2005 were included. The primary objective was to document the effect of neutropenic complications on delivery of ABVD chemotherapy in HL patients. Secondary objectives were to investigate the incidence of CIN and febrile neutropenia (FN) and to compare US and EU practice with ABVD therapy in HL. Pooled data were analysed to explore univariate associations with neutropenic events. RESULTS: Chemotherapy delivery was suboptimal (with a relative dose intensity < or = 85%) in 18-22% of patients. The incidence of grade 4 CIN in cycles 1-4 was lower in US patients (US 24% vs. EU 32%). Patients in both the US and the EU experienced similar rates of FN across cycles 1-4 (US 12% vs. EU 11%). Use of primary colony-stimulating factor (CSF) prophylaxis and of any CSF was more common in the US than the EU (37% vs. 4% and 78% vs. 38%, respectively). The relative risk (RR) of dose delays was 1.54 (95% confidence interval [CI] 1.08-2.23, p = 0.036) for patients with vs. without grade 4 CIN and the RR of grade 4 CIN was 0.35 (95% CI 0.12-1.06, p = 0.046) for patients with vs. without primary CSF prophylaxis. CONCLUSIONS: In this population of HL patients, CIN was frequent and FN occurrence clinically relevant. Chemotherapy delivery was suboptimal. CSF prophylaxis appeared to reduce CIN rates.
dc.format.extent 27 - ?
dc.language ENG
dc.language.iso en_US en_US
dc.relation.ispartof J Hematol Oncol
dc.relation.isversionof 10.1186/1756-8722-3-27
dc.subject Adult
dc.subject Aged
dc.subject Aged, 80 and over
dc.subject Antineoplastic Combined Chemotherapy Protocols
dc.subject Bleomycin
dc.subject Colony-Stimulating Factors
dc.subject Dacarbazine
dc.subject Doxorubicin
dc.subject Female
dc.subject Hodgkin Disease
dc.subject Humans
dc.subject Male
dc.subject Middle Aged
dc.subject Neutropenia
dc.subject Prospective Studies
dc.subject Vinblastine
dc.title Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery.
dc.title.alternative en_US
dc.type Journal Article
dc.description.version Version of Record en_US
duke.date.pubdate 2010-8-19 en_US
duke.description.endpage 27 en_US
duke.description.issue en_US
duke.description.startpage 27 en_US
duke.description.volume 3 en_US
dc.relation.journal Journal of Hematology & Oncology en_US
pubs.author-url http://www.ncbi.nlm.nih.gov/pubmed/20723212
pubs.organisational-group /Duke
pubs.organisational-group /Duke/School of Medicine
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments/Medicine
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments/Medicine/Medicine, Medical Oncology
pubs.publication-status Published online
pubs.volume 3
dc.identifier.eissn 1756-8722

Files in this item

This item appears in the following Collection(s)

Show simple item record